BYOT.L Regulatory News (BYOT)

16 Oct 2006 07:01

The Directors of Byotrol plc (the "Company") are pleased to announce the outcomeof a six month study conducted at the Glasgow Royal Infirmary to measure theefficacy of the Company's anti-microbial technology in combating the spread ofMethicillin Resistant Staphylococcus Aureus ("MRSA") within a working hospitalward environment. The study was staged in two ward areas with Vascular Surgery at Glasgow RoyalInfirmary which because of the nature of conditions and patients treated had apotential for high incidence of MRSA infection. One of the wards was cleanedwith Byotrol and the other with existing cleaning agents. The independently supervised study showed that daily cleaning with Byotrol'spatented biocide of the ward's high contact surfaces, including door handles,tables, television handsets, patient contact systems and bed rails, representinga small fraction of the total surfaces within the ward, resulted in asignificant reduction in the incidence of MRSA. The cleaning regimen, which required no special equipment or extra resource, waspractised for 4 months and the incidence of MRSA was shown to have been reducedby 75% against the pre-trial condition of the ward. During this phase there weretest periods with no incidence of MRSA. Furthermore, the number of hospital acquired cases of MRSA was seen to be 50%higher in the area of the ward where a conventional disinfectant was usedcompared to that where Byotrol was used. This was achieved as a result ofByotrol's residual action on surfaces against micro-organisms even after it hasdried. The study was independently supervised by Professor Curtis Gemmell, Professor ofBacterial Infection and Epidemiology at the University of Glasgow who workedclosely with the hospital's Vascular Surgery team. Professor Gemmell is also adirector of the Scottish Methicillin Resistant Staphylococcus Aureus (MRSA)Reference Laboratory and an appointed adviser to Byotrol on the requirements ofthe NHS and control of infection in healthcare. Professor Gemmell will today be presenting a paper based on the study to medicaland infection control professionals at the 6th international conference of theHospital Infection Society in the Netherlands. Stephen Falder, Byotrol's Deputy Chairman commented: "This independent study has demonstrated the outstanding effectiveness ofByotrol in a working hospital environment. Byotrol was used by the existingcleaning staff, with no risk or disturbance to patients or healthcareprofessionals and with no requirement for expensive equipment. The Directorsbelieve that the results of the study further pave the way for the Company toachieve significant sales into the healthcare sector." \* TFinancial calls to: Stephen Falder 07767 404629Deputy Chairman 0161 277 9518Byotrol plc David McRobbie 07739 549226Chief ExecutiveByotrol plc Charles Stanley Securities 020 7149 6457Philip Davies Media Calls to: Allan Piper 0207 436 7486First City PR Jim RothnieMcCann Erickson PR 01625 822540\* T Copyright Business Wire 2006